The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

A wide range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibodies (mAbs) have been reported, most of which target the spike glycoprotein. Therapeutic implementation of these antibodies has been challenged by emerging SARS-CoV-2 variants harboring mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: Makdasi, Efi, Zvi, Anat, Alcalay, Ron, Noy-Porat, Tal, Peretz, Eldar, Mechaly, Adva, Levy, Yinon, Epstein, Eyal, Chitlaru, Theodor, Tennenhouse, Ariel, Aftalion, Moshe, Gur, David, Paran, Nir, Tamir, Hadas, Zimhony, Oren, Weiss, Shay, Mandelboim, Michal, Mendelson, Ella, Zuckerman, Neta, Nemet, Ital, Kliker, Limor, Yitzhaki, Shmuel, Shapira, Shmuel C., Israely, Tomer, Fleishman, Sarel J., Mazor, Ohad, Rosenfeld, Ronit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379094/
https://www.ncbi.nlm.nih.gov/pubmed/34464610
http://dx.doi.org/10.1016/j.celrep.2021.109679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379094/
https://www.ncbi.nlm.nih.gov/pubmed/34464610
http://dx.doi.org/10.1016/j.celrep.2021.109679

Ejemplares similares